关键信息
-
基因名
B7-2/CD86
- 应用
-
别名
T-Lymphocyte Activation Antigen CD86; Activation B7-2 Antigen; B70; BU63; CTLA-4 Counter-Receptor B7.2; FUN-1; CD86; CD28LG2
-
种属
Human
-
表达系统
HEK293
-
标签
C- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P42081
-
表达区间
24-247aa
-
分子量
26.69 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
B7-2 (also known as CD86) is a key co-stimulatory molecule expressed on the surface of antigen-presenting cells (APCs) that plays a crucial role in T cell activation and the immune response. It functions by binding to the CD28 and CTLA-4 receptors on T cells, providing essential signals that promote T cell proliferation, differentiation, and survival. The study of B7-2/CD86 recombinant proteins has gained significant attention in immunology due to their potential applications in cancer immunotherapy, autoimmune diseases, and transplant rejection. Researchers have focused on characterizing the structural and functional properties of B7-2/CD86, as well as developing recombinant forms for therapeutic use. These recombinant proteins can enhance T cell responses by mimicking natural interactions that stimulate the immune system or can be utilized in the creation of checkpoint inhibitors to modulate immune responses in tumor environments. Additionally, understanding the interactions between B7-2/CD86 and its receptors aids in deciphering the mechanisms of immune regulation, which is crucial for designing effective interventions in immune-related disorders. As a result, the exploration of B7-2/CD86 recombinant proteins contributes to advancing both basic immunological knowledge and the development of novel therapeutic strategies aimed at harnessing or downregulating immune responses for clinical benefit.
